Loading patent…
AssigneeNew York University
InventorsMartin J. Blaser, Ilseung Cho
Estimating the term…
The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.
A method of treating a disease in a mammal comprising administering to the mammal a therapeutically effective amount of a probiotic composition comprising one or more bacterial strains, wherein the composition (i) stimulates growth and/or activity of bacteria which are under-represented in microbiota of the mammal as compared to healthy subjects and/or (ii) inhibits growth and/or activity of bacteria which are over-represented in microbiota of the mammal as compared to healthy subjects.
A method for treating asthma, allergy, gastrointestinal reflux disease (GERD), or eosinophilic esophagitis in a mammal comprising administering to the mammal a therapeutically effective amount of H. pylori cagA positive (cagA +) strain.
A method for treating a disease associated with antibiotic treatment in a mammal comprising (i) stimulating growth and/or activity of bacteria which have been depleted as a result of antibiotic treatment and/or (ii) inhibiting growth and/or activity of bacteria which are over-represented as a result of antibiotic treatment.
A method for restoring at least one bacterial strain depleted as a result of antibiotic treatment or disease in a mammal comprising:
A method for restoring a function of microbiota affected by antibiotic treatment or disease in a mammal comprising:
A method for treating obesity and related disorders in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic or probiotic composition which lower the levels of Butyryl CoA transferase (BCoAT) enzyme in gastrointestinal microbiota of the mammal.
A method for treating obesity and related disorders in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic or probiotic composition which alters gastrointestinal microbiota of the mammal to lower the level of gastric inhibitory polypeptide (GIP) in the serum of the mammal.
A method for treating obesity and related disorders in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic or probiotic composition which increases the ratio of the phyla Bacteroidetes to Firmicutes (B/F ratio) in the gastrointestinal microbiota of the mammal.
A method for diagnosing obesity and related disorders in a mammal comprising comparing the total number of Butyryl CoA transferase (BCoAT)-encoding genes in gastrointestinal microbiota of the mammal and in healthy control gastrointestinal microbiota, wherein the increased levels of BCoAT genes are indicative of the disorder.
A method for diagnosing obesity and related disorders in a mammal comprising comparing the ratio of the phyla Bacteroidetes to Firmicutes (B/F ratio) in the gastrointestinal microbiota of the mammal and in healthy control gastrointestinal microbiota, wherein the decreased B/F ratio is indicative of the disorder.
Dependencies are inferred from the claim text.